Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore

Agilent Technologies (NYSE:A | A Price Prediction) heads into a pivotal earnings setup for retirement-oriented portfolios, with a company-confirmed Q3 2026 report after the close on Aug. 26 arriving on top of a raised guide, expanding margins, and a fresh product cycle that management already said Ignite pulled forward by a full quarter. Every operating lever is pointing the same direction, leaving little room for a coin-flip outcome.

Beat-and-Raise Momentum Is Already Compounding

Agilent walked out of Q2 with revenue of $1.835 billion, up 10.01% year over year, non-GAAP EPS of $1.49 versus a $1.4083 estimate (a 5.8% surprise), and non-GAAP operating margin of 26.4%, up 130 basis points. Net income jumped 57.67%. Management then raised the full year to $7.39B–$7.49 billion in revenue and $6 to$6.10 in EPS. The Q3 guide of $1.83 billion to $1.85 billion in revenue and $1.48–$1.50 EPS is the number to clear, and the last beat produced a 16.87 day-of-change.

Catalyst Stack: 9500 ICP-MS, Replacement Cycle, Ignite

The 9500 triple quad ICP-MS launch was expedited by a full quarter via Ignite, and Agilent has now printed a book-to-bill above one for nine consecutive quarters. Instrument revenue grew high single digits with LC, LC-MS, and GC in the low double digits. Pricing delivered roughly 200 basis points in Q2, double the original full-year goal. This is a durable margin story into a live replacement cycle.

Valuation and the Head-to-Head

Agilent trades at a forward P/E of 22 with an analyst target of $160.11 and 17 Buy or Strong Buy ratings against zero Sell ratings. Compare that to Waters Corporation (NYSE:WAT), which is still digesting the BD Biosciences deal. Waters posted a Q2 net loss of $136 million against $232 million of intangible amortization and $155 million of inventory step-up charges, with organic constant-currency growth of 9%. Against Thermo Fisher Scientific (NYSE:TMO), Agilent’s 26.4% operating margin beats Thermo’s 22.8% adjusted operating margin, and Agilent grew reported revenue faster in Q2 (10.01% versus Thermo’s 10.49% with far less acquisition help). Cleaner P&L, better margin, same growth.

Only Real Risk, Dismissed

Bears point to the Q1 FY2026 miss (EPS $1.36 versus $1.3683), but management tied it to a U.S. snowstorm in the final week and still raised full-year guidance. Q2 answered with a clean beat and another raise. The stock is now up more than 22% in one month and 33.5% over the past year, and it still sits below the $160.11 analyst target.

Keep an eye on the stock into the August 26 close.

Contact [email protected] for any questions or corrections.